[{"orgOrder":0,"company":"OMERS Life Sciences","sponsor":"Xencor","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Antibody","year":"2023","type":"Divestment","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"OMERS Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OMERS Life Sciences \/ Xencor","highestDevelopmentStatusID":"15","companyTruncated":"OMERS Life Sciences \/ Xencor"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Danicopan","moa":"||Factor D","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Danicopan","moa":"||Factor D","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alexion Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Danicopan","moa":"||Factor D","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Danicopan","moa":"||Factor D","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Danicopan","moa":"||Factor D","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Danicopan","moa":"||Factor D","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Ravulizumab-cwvz

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : Voydeya (danicopan) is a first-in-class oral medicine in development as an add-on to C5 inhibitors for patients with PNH and residual hemolytic anemia.

                          Product Name : Voydeya

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 23, 2024

                          Lead Product(s) : Danicopan,Ravulizumab

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : Ultomiris (ravulizumab) is approved in the US as the first long-acting C5 complement inhibitor for patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.

                          Product Name : Ultomiris

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          March 25, 2024

                          Lead Product(s) : Ravulizumab

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Approved FDF

                          Sponsor : AstraZeneca

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : Voydeya (danicopan) is an investigational oral medicine being developed as an add-on to C5 inhibitors for patients with PNH and residual hemolytic anemia.

                          Product Name : Voydeya

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 26, 2024

                          Lead Product(s) : Danicopan,Ravulizumab

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : Voydeya (danicopan) is a first-in-class oral Factor D inhibitor. It is approved in combination with Ultomiris or Soliris for the treatment of paroxysmal nocturnal haemoglobinuria (PNH).

                          Product Name : Voydeya

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 19, 2024

                          Lead Product(s) : Danicopan,Ravulizumab

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : Voydeya (danicopan) is a first-in-class oral medicine being developed as an add-on to C5 inhibitors for patients with PNH and residual hemolytic anemia.

                          Product Name : Voydeya

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 04, 2024

                          Lead Product(s) : Danicopan,Ravulizumab

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : Ultomiris (ravulizumab), the first and only long-acting C5 complement inhibitor, provides immediate, complete and sustained complement inhibition. It is EU approved for the treatment of neuromyelitis optica spectrum disorder.

                          Product Name : Ultomiris

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          October 05, 2023

                          Lead Product(s) : Ravulizumab

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          OMERS Life Sciences

                          Country arrow
                          AAN
                          Not Confirmed

                          OMERS Life Sciences

                          Country arrow
                          AAN
                          Not Confirmed

                          Details :

                          Product Name : Ultomiris

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          July 11, 2023

                          Lead Product(s) : Ravulizumab

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Approved FDF

                          Sponsor : Xencor

                          Deal Size : $215.0 million

                          Deal Type : Divestment

                          blank

                          08

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : Ultomiris (ravulizumab), the first and only long-acting C5 complement inhibitor, provides immediate, complete and sustained complement inhibition. It is being recommended for the treatment of neuromyelitis optica spectrum disorder.

                          Product Name : Ultomiris

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          June 09, 2023

                          Lead Product(s) : Ravulizumab

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : Ultomiris (ravulizumab), the first and only long-acting C5 complement inhibitor, provides immediate, complete and sustained complement inhibition. It is being recommended for the treatment of neuromyelitis optica spectrum disorder.

                          Product Name : Ultomiris

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          May 26, 2023

                          Lead Product(s) : Ravulizumab

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : Ultomiris (ravulizumab), the first and only long-acting C5 complement inhibitor, provides immediate, complete and sustained complement inhibition. It is being recommended for the treatment of neuromyelitis optica spectrum disorder.

                          Product Name : Ultomiris

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          March 04, 2023

                          Lead Product(s) : Ravulizumab

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank